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Abstract
Background In the 2014 WHO classification of endometrial hyperplasia (EH), complex EH is lumped together with simple 
EH in the benign category of non-atypical EH.
Objective To assess the risk of coexistent cancer in complex EH and simple EH without atypia, through a systematic review 
and meta-analysis.
Methods Electronic databases were searched from their inception to January 2019 for relevant articles.
Results Twelve studies assessing a total of 804 non-atypical EH were included. The risk of coexistent cancer was significantly 
higher in complex EH (12.4%) than in simple EH (2%), with an OR of 6.03 (p = 0.0002).
Conclusion Even in the absence of cytologic atypia, complex EH is associated with a significant risk of coexistent cancer. 
Further studies are necessary to investigate the need for a revision in the WHO classification.
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Introduction
Endometrial hyperplasia (EH) is a pathologic proliferation 
of endometrial glands, which may precede endometrial can-
cer of endometrioid type [1–4]. The stratification of the risk 
of cancer in EH is crucial to adopt an adequate and tailored 
patient management [5–8].
The endometrial intraepithelial neoplasia (EIN) classifi-
cation system highlights that some EH are benign hormone-
driven proliferation, which are referred to as “benign hyper-
plasia”, while other ones are monoclonal lesion, which are 
termed “EIN” and constitute true precursors of endometrial 
cancer [1, 3, 4, 9, 10]. The EIN system indicates glandular 
crowding, lesion size > 1 mm and cytologic features differ-
ent from background uncrowded endometrium as the crucial 
features to differentiate EIN from benign hyperplasia [1, 3, 
4, 9]. On the other hand, the current WHO classification 
gives crucial importance to cytologic atypia, defining “atypi-
cal EH” as premalignant and synonym of EIN, and “non-
atypical EH” as benign and synonym of benign hyperplasia 
[1–4, 9]. However, as we have pointed out in previous stud-
ies, non-atypical EH might include a significant number of 
premalignant lesions, which may be identified based on the 
complexity of glandular architecture [3, 11, 12].
In the present study, we aimed to assess how the complex-
ity of glandular architecture affects the risk of occult cancer 
in non-atypical EH. For this purpose, we first assessed the 
association between glandular complexity and risk of occult 
cancer, and then we quantified such risk separately for sim-
ple non-atypical EH (SEH) and complex non-atypical EH 
(CEH).
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 4-019-05299 -2) contains 
supplementary material, which is available to authorized users.
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Materials and methods
Review authors defined a priori criteria for electronic search, 
study selection, risk of bias assessment, data extraction and 
data analysis. All review stages were performed indepen-
dently by three authors (AT, AR, MM); in the case of disa-
greement, a solution was achieved by consensus among the 
three authors and with another author (GS).
The study was reported according to the Preferred 
Reporting Item for Systematic Reviews and Meta-analyses 
(PRISMA) statement [13].
Search strategy
Scopus, MEDLINE, Ovid, Web of Sciences; EMBASE, 
ClinicalTrial.gov, Cochrane Library and Google Scholar 
were searched from the inception of each database to Janu-
ary 2019. Several different searches were performed using 
a combination of the following text words: endometrial, 
endometrioid, endometrium, hyperplasia, intraepithelial 
neoplasia, complex, simple, atypia, atypical, precancer, pre-
malignant, precursor, cancer, carcinoma, adenocarcinoma, 
coexistent, occult, concurrent, hysterectomy, and risk. The 
search also involved all relevant references from eligible 
studies. No language restrictions were applied.
Study selection
All studies assessing the rate of occult endometrial cancer in 
women diagnosed with SEH and CEH were included. Occult 
endometrial cancer was defined as a cancer diagnosed on 
hysterectomy specimen after a preoperative diagnosis of 
endometrial hyperplasia. Exclusion criteria, defined a priori, 
were: overlapping patient data, case reports, reviews, and 
presence of endometrial cancer not assessed on hysterec-
tomy sample.
Risk of bias within studies assessment
The revised Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS-2) were used to assess the risk of bias 
within studies [14]. The four domains assessed were: (1) 
patient selection (were patients included consecutively or 
randomly?), (2) index test (were preoperative histologi-
cal slides reviewed by expert pathologists?), (3) reference 
standard (was hysterectomy specimens reviewed by expert 
pathologists?), and (4) flow and timing (was the time to hys-
terectomy < 1 year? In fact, cancers found after 1 year from 
the index diagnosis are usually considered as subsequently 
developed rather than coexistent [4, 9, 15, 16]). Authors’ 
judgements were “low risk”, “unclear risk” or “high risk” 
of bias for each domain and in each study. Concerns about 
applicability of the domains 1, 2 and 3 were also assessed 
(i.e., if the criteria adopted in the included study were cor-
rect but did not suit the aim of our review).
Data extraction
Data were extracted according to the PICOS: “Population” 
consisted of women diagnosed with non-atypical EH who 
underwent hysterectomy after a preoperative diagnosis of 
EH; “Intervention” (or risk factor) was the presence of a 
complex glandular architecture (CEH diagnosis); “Compara-
tor” was SEH; “Outcome” was the presence of endometrial 
cancer on histologic examination of hysterectomy specimen 
after the diagnosis of EH; “Study design” was the study 
design of the included studies.
Data analysis
The association of glandular complexity with occult cancer 
was assessed using odds ratio (OR) with 95% confidence 
interval (CI); a p value < 0.05 was considered as significant.
Subsequently, the pooled rate of occult cancer with 95% 
CI was assessed separately for SEH and CEH and reported 
graphically on forest plots to quantify the risk.
Statistical heterogeneity among studies was categorized 
based on the inconsistency index (I2) as follows: I2 = 0: null; 
0 < I2 < 25: minimal; 25 < I2 < 50: low; 50 < I2 < 75: moder-
ate; I2 > 75%: high.
A fixed effect model was adopted in the case of I2 < 50, 
while a random effect model was used in the case of I2 > 50.
The risk of bias across studies (publication bias) was 
assessed by reporting the studies on funnel plots of the 
logarithm of the OR by the standard error and of the rate of 
cancer by the standard error.
Comprehensive meta-analysis and Review Manager 5.3 
(Copenhagen: The Nordic Cochrane Centre, Cochrane Col-
laboration, 2014) were used for the analysis.
Results
Selection and characteristics of the studies
Twelve retrospective studies assessing a total of 804 EH 
were included [17–28]. Out of these, 566 were SEH and 
238 were CEH. The process of study selection is schema-
tized in Supplementary Fig. 1. Sampling methods included 
hysteroscopic biopsy, Pipelle biopsy, dilation and curettage 
and vacuum aspiration.
Characteristics of the included studies are shown in 
Table 1.
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Risk of bias assessment
For the domain 1 (patient selection), all studies were con-
sidered at low risk of bias, since they specified inclusion 
criteria and period of enrolment of patients.
For the domain 2 (index test), five studies were consid-
ered at low risk and the other ones at unclear risk. High 
concern about applicability was raised for one study, due 
to the possibility of SEH (non-atypical) being lumped 
together with simple atypical EH.
For the domain 3 (reference standard), the risk of bias 
was low in five studies and unclear in the other ones.
For the domain 4 (flow and timing), the risk of bias was 
low for eight studies (all patients underwent hysterectomy 
within 1 year from index diagnosis) and unclear for four 
studies (time to hysterectomy not specified, or inclusion 
of some patients with a time-to-hysterectomy > 1 year).
Authors’ judgements are shown in Supplementary 
Fig. 2.
Meta‑analysis
Among non-atypical EH, a diagnosis of CEH was signifi-
cantly associated with the presence of occult cancer on his-
tologic examination of hysterectomy specimen (p = 0.0002), 
with an OR of 6.02 (95% CI 2.35–15.42) and null statistical 
heterogeneity among studies (I2 = 0%) (Fig. 1). The funnel 
plot of OR was symmetrical, excluding a significant risk of 
publication bias (Fig. 2).
Among SEH, the pooled rate of coexistent cancer on hys-
terectomy specimen was 0.020 (95% CI 0.010–0.038), with 
null statistical heterogeneity among studies (I2 = 0%).
Among CEH, the pooled rate of coexistent cancer was 
0.124 (95% CI 0.084–0.181), with low heterogeneity among 
studies (I2 = 27%) (Fig. 3).
The funnel plot of the rate of coexistent cancer was sym-
metrical for both SEH and CEH, excluding a significant risk 
of publication bias (Fig. 4).
Discussion
Main findings and interpretation
Our study showed that the complexity of glandular archi-
tecture in EH was significantly associated with the presence 
of occult cancer, with a risk of 2% in SEH and of 12.4% in 
CEH.
The classification of EH has long since been a crucial 
issue [29–34]. It is essential to estimate the risk of cancer in 
women diagnosed with EH, as it determines the management 
of patients [35–39]. In fact, benign EH has a very low risk 
of coexistence or subsequent development of cancer (< 5%) 
and, thus, may be managed even by observation alone. On 
the other hand, the risk of cancer is high in EIN, making 
total hysterectomy the standard approach for this condition 
[4, 6, 9, 40].
To date, the WHO classification is the most widely used 
one for the diagnosis of EH [2, 4, 9]. According to the WHO, 
Table 1  Characteristics of the included studies
Study Country Period of enrolment Sample Age (mean) BMI Sampling method Time to hysterectomy
SEH CEH
1996 Dunton USA 1988–1993 18 4 34–81 (55.7) n.r Hysteroscopy, curettage, 
biopsy (unspecified)
Preoperative (mean 
2.4 months)
2001 Bettocchi Italy 1988–1991 25 11 (43) n.r Curettage ≤ 2 months
2002 Xie China 1992–2000 53 11 31–76 (48.5) n.r Curettage 4–90 days
2008 Obeidat Jordan 2003–2007 26 24 35–74 (51.8) n.r Curettage 1–33 weeks
2010 Yarandi Iran 2000–2005 30 4 30–86 (46.6) n.r Curettage ≤ 2 months
2011 Daud UK 1998–2009 117 34 (55.7) n.r Pipelle, curettage 2 weeks to 3 years 
(2 months)
2012 Yang China 2000–2011 5 41 37–69 n.r Biopsy (unspecified) ≤ 1 year
2014 Sirimusika Thailand 2000–2012 14 12 27–86 (47) (26.8) Curettage, hysteroscopy, 
biopsy (uspecified)
≤ 1 year
2015 Dolanbay Turkey 2009–2013 20 9 (54.6) (29.27) Pipelle, biopsy (unspeci-
fied)
< 6 weeks
2015 Kadirogullari Turkey 2006–2012 109 9 (50.5) (30.4) Biopsy (unspecified) Preoperative (unspecified)
2015 Matsuo USA 2003–2014 24 58 (45.2) (35.6) Pipelle, curettage 
vacuum aspiration,
4–2514 days (105 days)
2016 Boyraz Turkey 2007–2014 125 21 34–82 (50.4) n.r Biopsy (unspecified) Preoperative (unspecified)
Total – – 566 238 – – – –
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non-atypical EH is assimilated to benign EH, while atypical 
EH is assimilated to EIN [2, 4].
Our results showed that the risk of occult cancer is only 
2% in SEH, consistently with it being a benign condition. 
On the other hand, the risk of occult cancer is over 12% in 
CEH, i.e., about six times higher than SEH; this indicates 
that CEH cannot be simply regarded as a benign lesion.
In our previous studies on EH, we found that the EIN sys-
tem was more sensitive than the WHO system stratifying the 
risk of occult cancer [4]. On the other hand, no significant 
difference was found with regard to the risk of progression 
to cancer, probably due to the limited available data on the 
EIN system [9].
Furthermore, we showed that the altered expression of 
molecules involved in endometrial carcinogenesis, such as 
Bcl-2, β-catenin and PAX2, correlated better with the EIN 
criteria of premalignancy than with the WHO ones [11, 41, 
42]. By contrast, no difference was found regarding PTEN 
expression [43]; such finding may be due to overall low 
accuracy of PTEN loss as a marker of premalignancy [44, 
45].
Moreover, our results suggested the inconsistence of non-
atypical EH as a benign category. In fact, our previous stud-
ies showed that a complex glandular architecture increased 
the risk of progression to cancer of about six times [12] and 
that about half of CEH met EIN criteria of premalignancy 
[46].
All these findings suggest that the WHO criteria for 
benign hyperplasia might need a revision. In fact, consider-
ing CEH as an innocuous lesion may lead many patients to 
be undertreated, with the risk of progression to malignancy. 
However, it is clear that the risk of cancer in CEH is sensibly 
lower than in atypical EH; therefore, it appears excessive 
to address all CEH patients to hysterectomy, resulting in 
patients’ overtreatment instead.
As we proposed in our previous studies, a hypothetical 
solution might be the combination of WHO and EIN sys-
tems together to obtain a new integrated classification [4]. 
As the EIN system is more sensitive than WHO and better 
reflects molecular alterations, it could be used to distinguish 
benign functional EH from true premalignant lesions. On 
the other hand, the WHO criterion of cytologic atypia could 
distinguish premalignant lesions at lower risk (L-EIN) from 
premalignant lesion at higher risk (H-EIN) of coexistent can-
cer. Such a stratified diagnosis might be useful for the patient 
management. Firstly, a diagnosis of L-EIN might ensure 
that premalignant lesions without significant atypia are not 
misclassified as benign condition and then undertreated. 
Fig. 1  Forest plot of individual studies and pooled odds ratio (OR) for occult cancer in complex non-atypical hyperplasia (CEH) vs simple non-
atypical hyperplasia (SEH)
Fig. 2  Funnel plot of odds ratio (OR) by standard error (SE) for the 
risk of occult cancer in complex non-atypical hyperplasia (CEH) vs 
simple non-atypical hyperplasia (SEH)
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Secondly, patients with H-EIN might require hysterectomy 
in a shorter time compared to H-EIN, and a closer follow-up 
if conservatively treated. Thirdly, when the decision making 
between hysterectomy and conservative treatment is difficult 
(e.g., patient’s age older 40 years, low couple fertility poten-
tial, wish to get pregnant not in the short term, pluriparity), 
a diagnosis of L-EIN might direct the choice towards a con-
servative approach.
Further studies are of course needed to investigate the 
feasibility of such an integrated classification.
Strengths and limitations
To best of our knowledge, this is the first systematic review 
and meta-analysis assessing the risk of coexistent cancer in 
SEH and CEH.
A limitation to our results may lie in the selection of 
patients within the included studies. In fact, even though 
patients were selected consecutively, the selection was 
restricted to only those women who underwent hysterectomy 
within a short term. If we assume that the ratio between 
the risks of occult cancer in SEH and CEH is the same that 
in the general population, then the included studies could 
be considered as cohort studies, and the level of evidence 
for prognostic studies would be II; otherwise, the level of 
evidence would be III [47]. Large prospective studies are of 
course needed to confirm our results.
The low reproducibility in the classification of EH might 
be another limitation of our meta-analysis, as it is intrinsic 
to the topic assessed [48]. For this reason, we considered 
the index test (i.e., pathologic examination) at low risk of 
bias only if diagnoses were reviewed by expert pathologist. 
Fig. 3  Forest plot of individual studies and pooled rate of occult cancer in complex non-atypical hyperplasia (CEH) and simple non-atypical 
hyperplasia (SEH)
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Although the risk of bias in this domain was unclear for 
some studies, the statistical heterogeneity was null in the 
OR analysis, giving strength to our results.
Finally, the primary studies did not allow extracting 
demographic data separately for SEH and CEH. This might 
be a limitation, since factors as diabetes mellitus might affect 
the behavior of EH [49, 50]. However, the only study that 
reported demographics separately for the two groups [24] 
did not show significant differences.
Conclusion
CEH is associated with a significant risk of coexistent endo-
metrial cancer, about six times higher than SEH. Consider-
ing such category as benign may cause many patients to be 
undertreated. Therefore, a revision in the 2014 WHO clas-
sification criteria might be advisable; they do not consider 
complexity of glandular architecture in non-atypical EH.
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